Latigo Biotherapeutics, Inc.
Disrupt Pain Without Opioids. While other treatments dull pain, Latigo’s solutions target the source of pain before it reaches the central nervous system. The result is healing without dependence, and relief that can help restore quality of life.
Funding history
About Latigo Biotherapeutics, Inc.
How much funding has Latigo Biotherapeutics, Inc. raised?
Latigo Biotherapeutics, Inc. has raised $50.0M in total funding. The most recent round was Series B.
Where is Latigo Biotherapeutics, Inc. headquartered?
Latigo Biotherapeutics, Inc. is headquartered in Thousand Oaks, CA.
What does Latigo Biotherapeutics, Inc. do?
Disrupt Pain Without Opioids. While other treatments dull pain, Latigo’s solutions target the source of pain before it reaches the central nervous system. The result is healing without dependence, and relief that can help restore quality of life.
What problem does Latigo Biotherapeutics, Inc. solve?
Current pain treatments force tradeoffs between efficacy, safety, tolerability, and addiction risk, leaving many patients undertreated or exposed to addiction-prone therapies.
What's Latigo Biotherapeutics, Inc.'s solution?
Latigo is a clinical-stage biopharmaceutical company developing non-opioid pain medicines intended to rapidly and effectively stop pain transmission.
What makes Latigo Biotherapeutics, Inc. different?
The medicines are designed to relieve pain rapidly without the addiction risk associated with opioid-based pain treatments.
What makes Latigo Biotherapeutics, Inc. notable?
Latigo Biotherapeutics, based in Thousand Oaks and developing non-opioid pain therapeutics, has raised $290M across a $135M Series A and $150M Series B, with investors including Blue Owl Capital, Deep Track Capital, and the Qatar Investment Authority.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.